Nevia.bio is a health tech startup that operates in the women's health market, with a particular focus on early detection of diseases. The company's primary mission is to leverage innovative technologies, such as machine learning, to analyze vaginal secretions and detect diseases at an early stage. This approach is particularly relevant for conditions like ovarian cancer, often referred to as "the silent killer" due to its late-stage diagnosis in most cases.

Nevia's business model revolves around its proprietary machine learning platform, which is designed to identify diseases through the analysis of vaginal secretions. This platform is not only a potential game-changer in terms of early detection but also empowers women to take control of their health.

The company's primary clients are women worldwide, particularly those at risk of diseases that can be detected through vaginal secretions. By providing a tool for early detection, Nevia is addressing a significant gap in the market and meeting a growing demand for early-diagnosis solutions.

Nevia generates revenue by offering its machine learning platform for disease detection. While the specifics of their pricing model are not publicly available, it's likely that they charge either a subscription fee for regular use of their platform or a one-time fee for each analysis.

The team behind Nevia is a diverse group of individuals with backgrounds in healthcare, technology, and business. They have been recognized for their innovative approach, winning the Israeli Femtech Innovation Leadership Award and being named one of the top 20 most promising companies.

Keywords: Women's Health, Early Detection, Machine Learning, Vaginal Secretions Analysis, Ovarian Cancer, Health Tech, Innovative Technologies, Disease Diagnosis, Femtech, Israeli Innovation.